Chemotherapy combination regimen

This page covers all Chemotherapy combination regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin), Thymidylate synthase (5-FU), Topoisomerase I (irinotecan).

Targets

Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin) · Thymidylate synthase (5-FU), Topoisomerase I (irinotecan)

Marketed (3)

• Dose dense AC · Ottawa Hospital Research Institute · Oncology
  Dose-dense AC is a chemotherapy regimen that delivers doxorubicin and cyclophosphamide at higher doses over shorter intervals to maximize cytotoxic effect against cancer cells.
• TC · AGO Study Group · Oncology
  TC is a chemotherapy regimen combining docetaxel and cyclophosphamide, which work synergistically to inhibit cell division and induce apoptosis in cancer cells.
• TC chemotherapy · Agendia · Oncology
  TC chemotherapy is a combination regimen of docetaxel (Taxotere) and cyclophosphamide that disrupts microtubule dynamics and cross-links DNA to kill rapidly dividing cancer cells.

Phase 3 pipeline (17)

• Adriamycin+Cyclophosphamide>Docetaxel · Asan Medical Center · Oncology
  This sequential chemotherapy regimen uses anthracycline and alkylating agents followed by a taxane to damage cancer cell DNA and disrupt microtubule formation, inducing apoptosis in rapidly dividing cells.
• Course B2 +Vin · Children's Cancer Group, China · Oncology
  Course B2 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents to inhibit microtubule formation and induce apoptosis in cancer cells.
• FLOT scheme · Fujian Medical University · Oncology
  FLOT is a chemotherapy combination regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.
• FOLFOX regimen · MIPO Clinic · Oncology
  FOLFOX is a chemotherapy combination regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms.
• AG regimen · Tianjin Medical University Cancer Institute and Hospital · Oncology
  AG regimen is a chemotherapy combination regimen, typically consisting of adriamycin (doxorubicin) and gemcitabine, that works by damaging cancer cell DNA and inhibiting nucleotide synthesis to kill rapidly dividing cells.
• Docetaxel/capecitabine followed by XEC · China Breast Cancer Clinical Study Group · Oncology
  This regimen combines docetaxel (a microtubule-stabilizing chemotherapy) and capecitabine (a fluoropyrimidine prodrug) followed by XEC (a combination of cyclophosphamide, epirubicin, and 5-fluorouracil) to inhibit cancer cell division and induce apoptosis.
• Cisplatin+Vindesine+MMC/ concurrent radiation · West Japan Thoracic Oncology Group · Oncology
  This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms.
• Pure chemotherapy（Xelox） · The First People's Hospital of Hefei · Oncology
  Xelox is a chemotherapy regimen combining capecitabine and oxaliplatin that inhibits DNA synthesis and causes DNA cross-linking to kill rapidly dividing cancer cells.
• Consolidation, I HAM cycle · dr hab. n. med. Agnieszka Wierzbowska · Oncology
  The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells.
• B arm (FLAG-IDA) · Polish Adult Leukemia Group · Oncology
  FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis.
• TP regimen · Tianjin Medical University Cancer Institute and Hospital · Oncology
  TP regimen is a chemotherapy combination of docetaxel (Taxotere) and cisplatin that disrupts microtubule dynamics and DNA replication to kill cancer cells.
• EC to docetaxel or paclitaxel · RenJi Hospital · Oncology
  EC (epirubicin/cyclophosphamide) followed by docetaxel or paclitaxel is a sequential chemotherapy regimen that damages cancer cell DNA and disrupts microtubule function to inhibit tumor growth.
• IV Chemotherapy (Regimen 1) · UNICANCER · Oncology
  IV Chemotherapy Regimen 1 is a combination chemotherapy treatment that kills rapidly dividing cancer cells through DNA damage and cell cycle disruption.
• Modified Bolus 5-FU/LV with Irinotecan · Pfizer · Oncology
  This combination regimen inhibits DNA synthesis through fluorouracil and topoisomerase I inhibition via irinotecan, with leucovorin enhancing fluorouracil efficacy.
• Concurrent chemotherapy · Sun Yat-sen University · Oncology
  Concurrent chemotherapy administers multiple cytotoxic chemotherapy agents simultaneously or in close temporal proximity to enhance tumor cell death.
• G-CHOP · Nanjing Yoko Biomedical Co., Ltd. · Oncology
  G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.
• AG chemotherapy · Zhejiang Cancer Hospital · Oncology
  AG chemotherapy is a chemotherapeutic regimen combining doxorubicin and gemcitabine to inhibit cancer cell proliferation and induce apoptosis.